☕️ retweeted
This is one side of the story. There is another.
@approvedfm season 1 finale. Coming soon.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientific abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
☕️ retweeted
I was very good friends with Fiona, and suffice it to say and sparing the details, she did NOT care for Chelsea Clinton at all
☕️ retweeted
Sports journalist Mike Wise died Nov. 14 in Panama City. He was 62.
He was best known for his ability to write incisive columns on tight deadlines, but he also delved deeply into the motives and psyches of athletes, coaches and fans. wapo.st/4jmOnC9
☕️ retweeted
Pleased to report no negative effects from lack of sleep. With this information we can, um. It’s
☕️ retweeted
In the spring of 2023, Anthropic invited me to spend several weeks at their headquarters ahead of the launch of Claude 2, sitting in on meetings and interviewing dozens of employees to write the first major profile of the company in the NYT.
I just reread that story, and went back through my notebook in light of Anthropic's IPO. A few things that stuck out:
-- Anthropic was very small, very recently. When I visited, they had 160 employees in a small office on Sansome, a chatbot nobody had ever heard of, and seemed to have no interest in running a business. I wrote in my notebook that they seemed like "ambivalent capitalists"; their newly hired sales guy told me that the only reason he needed to make money at all was so that the safety researchers could save the world.
-- Things were not going well for them: their biggest shareholder (SBF) had been arrested for fraud, and OpenAI was eating their lunch with ChatGPT. (I later learned that they also had an expensive model training failure in 2023.) This was 3.5 years before they went public as one of the most valuable companies in the world, with 5,300 employees and 14x annual revenue growth. I guess they figured out the capitalism thing!
-- They were obviously and sincerely terrified of AI. Claude 2 was a very dumb model by today's standards, but every discussion I had there revolved around existential risk. Researchers told me they lost sleep over their fears of AI takeover, and made terrifying predictions of how soon AGI would arrive. It didn't seem fake or manufactured, but I didn't really get it! I wrote in my notebook: "I have never encountered a company that so badly needs a Klonopin." (I stand behind this, although I also need one now.)
-- Dario was in Italy when the NYT photographer wanted to take his picture, so his team rented an office in some random Italian town and staged it to look like his actual office, and they took the photos there. It had a rotary phone (?) and panic-room red lights, which I never really understood.
-- The Ants I talked to mostly struck me as sharp and thoughtful, although I did end up wondering whether they were too safety-obsessed to run an actual business. (I jotted down: "I do not know why you would invest in a company like this.") But I was struck by their earnestness, especially because I'd just spent several years covering social networks that didn't worry about the harms of their products at all.
Anyway, I'm feeling sort of conflicted about the Anthropic IPO. (As are a lot of people, including some at Anthropic!) I don't know if being public makes an AI company more or less likely to follow through on its safety commitments, and I know the company has changed a lot as it has grown. But on some level I'm also just like, damn, what a crazy story.
Here's the gift link, it's sort of fun to look back on the ancient runes of July 2023.
nytimes.com/2023/07/11/techn…
☕️ retweeted
I’ve been an investor and/or board member or otherwise associated with companies whose capabilities and revenues never matched what was stated.
The stories are rarely discussed transparently or disclosed.
More often, the companies disappear from public view through an “acquisition.”
Many employees—protective of their personal legacy or silenced by non-disclosure agreements—say little.
And investors—protective of their personal or corporate brands with their limited partners—also say nothing.
I wonder sometimes how people—board members, customers, employees, investors—end up associated with companies whose capabilities are fictions or non-truths.
The most dramatic example of this is Theranos (check out “You Can See Everything” if you haven’t already).
But there are many Theranoses on a smaller scale—both free-standing companies and groups within larger corporations.
How does this happen?
I think it really comes down to a few things:
1. Inattention. We are paying attention in name only. We attend meetings and review presentations, but we aren’t sufficiently curious. And when we are curious, we too readily accept superficial answers.
2. Excessive deference to experts. We believe others know more than we do. We assume someone else has done the diligence, validated the technology, or asked the hard questions. Sometimes nobody has.
3. “Fake it till you make it” taken to an extreme. Many companies oversell their capabilities. But some never actually “make it.” At some point, aspiration becomes misrepresentation, and the company becomes trapped by its own narrative.
4. Moral decay. We normalize the abnormal. Small exaggerations become larger ones. Lying becomes how we do business, and some companies develop cultures where telling the truth becomes an act of disloyalty.
5. Self-preservation. Investors don’t want to acknowledge losses. Board members don’t want to admit they missed something. Employees don’t want to jeopardize their careers. Everyone has a reason to stay silent, and few have an incentive to speak up.
What troubles me most is that these situations rarely produce meaningful accountability or learning.
People move on. Reputations remain largely intact. And the same patterns repeat themselves.
In my forthcoming book, The Moral Alibi, I explore how otherwise good people and organizations rationalize practices that they would once have regarded as unacceptable.
I think these corporate fictions are another manifestation of the same problem.
We lose our moral attention. We stop asking questions. We convince ourselves that someone else knows better—or that speaking up isn’t worth the cost.
And perhaps that’s the most uncomfortable lesson.
The most dangerous deceptions aren’t sustained by dishonest people alone.
They’re sustained by otherwise good people who find reasons not to ask, not to look, and not to speak.
☕️ retweeted
And as a result, the Tasmanian Government has published one one of the greatest Government Documents I have ever seen
☕️ retweeted
𝐉𝐞𝐟𝐟𝐞𝐫𝐢𝐞𝐬 𝐋𝐨𝐧𝐝𝐨𝐧 𝟐𝟎𝟐𝟔: A top biotech CEO (@Roivant's @gline) and top investor (Affinity Asset Advisors' @pnosker) talk running biotech companies and investing in them. $ROIV
Watch the full discussion: biotechtv.com/post/jefferies…
☕️ retweeted
It looks like I was wrong about Sellas Life Sciences $SLS and its experimental blood cancer immunotherapy.
On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia – an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.
Story here:
statnews.com/2026/11/17/sell…
☕️ retweeted
Ben Slate (SAC Capital): "It’s totally unacceptable to bet 1/2 billion dollars on alzhemiers without a real discussion with wayne, mat and steve."
☕️ retweeted
Ashlee B. Gabrysch: A City of Chicago CFO has to tell the truth. So here’s why I resigned. chicagotribune.com/2026/11/1…





































